Lemtrada

Type: Product
Name: Lemtrada
First reported Apr 19 2014 - Updated Apr 19 2014 - 1 reports

M.S. patients here hope for access to drug that works

Robert "Buddy" Allen, 51, was diagnosed with multiple sclerosis in 2005.When Robert "Buddy" Allen could no longer run after a Frisbee, he thought the cause was an old childhood injury -- when he got hit by a car.For more information on the multiple sclerosis ... [Published Gainesville Sun - Apr 19 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Genzyme to Resubmit LemtradaTM Application for FDA Review

(NewsRx) -- By a News Reporter-Staff News Editor at Biotech Business Week -- Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced that following constructive discussions with the U.S. Food and Drug Administration (FDA) the company plans to ... [Published NewsRX - Apr 18 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

New drug offers new hope for MS patients in Canada

Roughly 100,000 Canadians are living with multiple sclerosis and many manage the disease with a strict medication regime.Text + RESET -Roughly 100,000 Canadians are living with multiple sclerosis and many manage the disease with a strict medication r ... [Published TheLoop.ca - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

GENZYME : to Resubmit LemtradaTM Application for FDA Review

By a News Reporter-Staff News Editor at Pharma Business Week -- Genzyme , a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced that following constructive discussions with the U.S. Food and Drug Administration (FDA) the company plans to resubmit in ... [Published 4 Traders - Apr 17 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Sanofi to File for Lemtrada Approval Again

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.Sanofi ( SNY - Analyst Report ) announced that ... [Published Zacks.com - Apr 08 2014]
First reported Apr 07 2014 - Updated Apr 08 2014 - 2 reports

Patients investors react to Genzymes retry for approval of MS drug Lemtrada

Melissa Burdick, a 49-year-old patient with multiple sclerosis who filed a citizen's petition in support of U.S. approval of Lemtrada, said she was "thrilled" to hear the company is ... ... [Published Big News Network - Apr 08 2014]
First reported Apr 07 2014 - Updated Apr 08 2014 - 9 reports

Genzyme to reapply for MS drug approval

Genzyme plans to resubmit its application to U.S. regulators for its multiple sclerosis (MS) treatment, the Cambridge-based drug maker said Monday.Genzyme said it has had constructive discussions with the U.S. Food and Drug Administration (FDA) after ... [Published WBJournal.com - Apr 08 2014]
First reported Apr 06 2014 - Updated Apr 07 2014 - 20 reports

Genzyme Announces it Will Resubmit Lemtrada Application to the FDA

/About-the-Society/News/Genzyme-Announces-it-Will-Resubmit-Lemtrada-Applic ... [Published MS News - Apr 07 2014]
Entities: Lemtrada, Genzyme Corp
First reported Apr 04 2014 - Updated Apr 04 2014 - 3 reports

UK’s NICE says “yes” to Genzyme’s MS drug Lemtrada

In final draft guidance, UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has recommended the use of French drug major Sanofi (Euronext: SAN) subsidiary Genzyme’s multiple sclerosis drug Lemtrada (alemtuzumab).The NICE is ... [Published Pharma Letter - Apr 04 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 2 reports

Physicians Protest FDA's Rejection Of Genzyme's Lemtrada For Multiple Sclerosis

By Cyndi RootThe doctors who participated in clinical trials of Lemtrada, a multiple sclerosis (MS) drug, are protesting the Food and Drug Administration’s (FDA) decision to reject the medication. Alasdair J. Coles and Alastair Compston, along with a ... [Published Pharmaceutical Online - Mar 31 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 1 reports

Genzyme : Lemtrada Approved for Treatment of Multiple Sclerosis in Brazil

Genzyme , a Sanofi company, announced that Brazil's national health surveillance agency, ANVISA, has approved Lemtrada for the treatment of patients with relapsing forms of multiple sclerosis to slow or reverse the accumulation of physical disability ... [Published 4 Traders - Mar 26 2014]
First reported Mar 24 2014 - Updated Mar 25 2014 - 2 reports

Brazil health agency approves Genzyme’s Lemtrada to treat multiple sclerosis

ANVISA, Brazil’s national health surveillance agency, has approved Sanofi company Genzyme's Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS) to slow or reverse the accumulation of physical disability ... [Published Pharmaceutical Business Review - Mar 25 2014]

Quotes

"Dr. Kantor would actually talk to me about each one" Allen said
"For me, it's fatigue that wipes me out. The pain wipes me out," says Brown. "I have mild cognitive impairment that makes it really hard for me to even doI write and I find it very difficult do that."

More Content

All (133) | News (72) | Reports (0) | Blogs (47) | Audio/Video (0) | Fact Sheets (0) | Press Releases (13)
sort by: Date | Relevance
M.S. patients here hope for access to drug that... [Published Gainesville Sun - Apr 19 2014]
Genzyme to Resubmit LemtradaTM Application for ... [Published NewsRX - Apr 18 2014]
New drug offers new hope for MS patients in Canada [Published TheLoop.ca - Apr 17 2014]
GENZYME : to Resubmit LemtradaTM Application fo... [Published 4 Traders - Apr 17 2014]
European neurologists expect Biogen Idec’s Tecf... [Published Pharma Letter - Apr 16 2014]
Catalent inks a biosimilar alliance with a Chin... [Published Fierce CRO - Apr 14 2014]
East Coast Biotech Roundup: Agios, Spero, Cerul... [Published Xconomy - Apr 11 2014]
Sibling, unrelated-donor HSCT conferred similar... [Published Orthopedics Today - Apr 10 2014]
NICE likely to back use of IV drug for multiple... [Published Nursing Times - Apr 10 2014]
Mitigating Lemtrada Risks with a Biomarker [Published Multiple Sclerosis Research - Apr 09 2014]
Sanofi to File for Lemtrada Approval Again [Published Zacks.com - Apr 08 2014]
Competitor Analysis: Biosimilar and Biosuperior... [Published Asian Hospital & Healthcare Management - Apr 08 2014]
Patients investors react to Genzymes retry for ... [Published Big News Network - Apr 08 2014]
Genzyme to reapply for MS drug approval [Published WBJournal.com - Apr 08 2014]
Patients, investors react to Genzyme’s retry fo... [Published Boston Business Journal - Apr 08 2014]
Sanofi to resubmit Lemtrada sBLA for US FDA's r... [Published Individual.com - Apr 08 2014]
Genzyme to resubmit bid for MS drug approval [Published Boston Globe - Apr 08 2014]
Genzyme resubmits drug to FDA [Published Boston Herald - Apr 08 2014]
News April 07, 2014 EDT Genzyme to Resubmit Lem... [Published Genzyme - Apr 08 2014]
Genzyme to Resubmit LemtradaTM Application for ... [Published Noodls - Apr 08 2014]
Makers of MS drug to try again for FDA approval [Published WSBTV - Apr 07 2014]
Genzyme to resubmit application for multiple sc... [Published Big News Network - Apr 07 2014]
Genzyme Resubmits Lemtrada to the FDA [Published News from MSAA - Apr 07 2014]
Overbought Levels Pose Downside Risk [Published RTTNews.com - Apr 07 2014]
Genzyme Announces it Will Resubmit Lemtrada App... [Published MS News - Apr 07 2014]
Sanofi misled investors with rosy Lemtrada pred... [Published FiercePharma - Apr 07 2014]
Genzyme to resubmit application for multiple sc... [Published Boston Business Journal - Apr 07 2014]
Sanofi to resubmit Lemtrada application for FDA... [Published Big News Network - Apr 07 2014]
Genzyme to resubmit Lemtrada NDA for FDA review [Published Pharma Letter - Apr 07 2014]
Genzyme to resubmit Lemtrada application [Published Seeking Alpha - Apr 07 2014]
1 2 3 4 5
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Mitigating Lemtrada Risks with a Biomarker [Published Multiple Sclerosis Research - Apr 09 2014]
Predicting Autoimmunity after Alemtuzumab Jones JL, Phuah CL, Cox AL, Thompson SA, Ban M, Shawcross J, Walton A, Sawcer SJ, Compston A,Coles AJ. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte ...
Genzyme Resubmits Lemtrada to the FDA [Published News from MSAA - Apr 07 2014]
Genzyme Resubmits Lemtrada to the FDAApril 7, 2014 Genzyme, a Sanofi company announced today that they will resubmit its supplemental Biologics License Application (sBLA) for approval of Lemtrada (alemtuzumab) for relapsing forms of multiple sclerosis, ...
Genzyme Announces it Will Resubmit Lemtrada App... [Published MS News - Apr 07 2014]
/About-the-Society/News/Genzyme-Announces-it-Will-Resubmit-Lemtrada-Applic ...
Genzyme to Resubmit Lemtrada™ Application for F... [Published Multiple Sclerosis Foundation News - Apr 07 2014]
Genzyme plans to resubmit in the second quarter its supplemental Biologics License Application (sBLA) seeking approval of Lemtrada™ (alemtuzumab) for the treatment of relapsing forms of multiple sclerosis, according to a statement issued by the ...
Genzyme to Resubmit LemtradaTM Application for ... [Published Business Wire Health News - Apr 07 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT:SAN and NYSE:SNY), announced today that following constructive discussions with the U.S. Food and Drug Administration (FDA) the company plans to resubmit in the second quarter its ...
1 2 3 4 5 6 7 8 9 10

Press Releases

sort by: Date | Relevance
Sanofi: Genzyme to Resubmit Lemtrada Applicatio... [Published GlobeNewswire: Acquisitions News - Apr 07 2014]
Genzyme to Resubmit LemtradaTM Application for ... [Published Genzyme Press Release - Apr 07 2014]
Genzyme to Resubmit Lemtrada™ Application for F... [Published Sanofi.com - Last press releases - Apr 07 2014]
Genzyme’s Lemtrada™ Approved in Brazil for Trea... [Published Genzyme Press Release - Mar 21 2014]
Pomerantz Law Firm Reminds Shareholders With Lo... [Published GlobeNewswire: Advertising News - Feb 07 2014]
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.